After a process lasting nearly a year and management presentations to multiple potential buyers, Boston Scientific CEO Mike Mahoney settled on SERB Specialty Pharmaceuticals, a Belgian company with a French culture and French CEO in Jeremie Urbain, as the company to buy out BTG plc’s Specialty Pharma business.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?